Compositions for stimulation of mammalian innate immune resistance to pathogens

Patent metadata

Field	Value
Publication number	US-9504742-B2
Application number	US-201514862884-A
Country	US
Kind code	B2
Filing date	Sep 23, 2015
Priority date	Mar 25, 2009
Publication date	Nov 29, 2016
Grant date	Nov 29, 2016

Abstract

Embodiments of the invention are directed to methods of treating, inhibiting or attenuating a microbial infection in an individual who has or is at risk for developing such an infection, comprising the step of administering an effective amount of a StIR composition to the individual.

First claim

The invention claimed is:

1. A method of inhibiting or attenuating a viral infection comprising administering an effective amount of a TLR9 agonist oligodeoxynucleotide (ODN) and PAM2CSK4 to an individual that has or is at risk of developing or acquiring a viral infection, wherein the composition does not further comprise an active ingredient that is an antigen.

2. The method of claim 1 , wherein the TLR9 agonist is a type C ODN.

3. The method of claim 2 , wherein the type C ODN is ODN2395 or ODNM362 or ODN10101.

4. The method of claim 1 , wherein the subject has been exposed to a pathogenic virus.

5. The method of claim 1 , wherein the virus is Adenoviridae, Coronaviridae, Filoviridae, Flaviviridae, Hepadnaviridae, Herpesviridae, Orthomyxoviridae, Paramyxovirinae, Pneumovirinae, Picornaviridae, Poxyiridae, Retroviridae, Togaviridae, Parainfluenza, Influenza, H5N1, Marburg, Ebola, Severe acute respiratory syndrome coronavirus, Yellow fever, Human respiratory syncytial, Hantavirus, or Vaccinia virus.

6. The method of claim 1 , wherein the TLR9 agonist and PAM2CSK4 are administered in a nebulized or aerosolized formulation.

7. The method of claim 1 , wherein the effective amount of the TLR9 agonist and PAM2CSK4 are deposited in the lungs of the individual.

8. The method of claim 1 , wherein the TLR9 agonist and PAM2CSK4 are administered in an amount of from about 0.1 mg/kg to about 100 mg/kg of the individual's body weight.

9. The method of claim 1 , wherein administering both the TLR9 agonist and PAM2CSK4 attenuates said viral infection.

10. The method of claim 1 , wherein the TLR9 agonist and PAM2CSK4 are essentially free of pathogenic microbes.

11. A method of inhibiting or attenuating a viral infection comprising administering an effective amount of a TLR9 agonist ODN and PAM2CSK4 in the same or separate compositions to an individual that has or is at risk of developing or acquiring the viral infection, wherein the same or separate compositions does not further comprise an active ingredient that is an antigen, and wherein administering both the ODN and PAM2CSK4 inhibits or attenuates said viral infection.

12. A method of stimulating innate resistance in an individual comprising administering a TLR9 agonist ODN and PAM2CSK4 in the same or separate compositions to an individual that has or is at risk of developing or acquiring a viral infection, wherein the same or separate compositions does not further comprise an active ingredient that is an antigen, wherein administering both the ODN and PAM2CSK4 stimulates innate resistance that inhibits a viral infection in the individual.

Assignees

• Univ Texas

Inventors

• Dickey Burton
• Tuvim Michael
• Evans Scott

Classifications

• A61P37/04

  Immunostimulants · CPC title

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P31/22

  for herpes viruses · CPC title

• A61P29/00

  Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] · CPC title

• A61P31/02

  Local antiseptics · CPC title